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Nasopharyngeal carcinoma (NPC), which is closely associated with the Epstein-Barr virus (EBV), is a highly
metastatic malignant tumor. An important activity in tumor invasion and metastasis is that of the 92-kDa type
IV collagenase or gelatinase, matrix metalloproteinase 9 (MMP-9), which mediates the degradation of the
basement membrane and extracellular matrix. The expression of MMP-9 has been shown to be enhanced by
the EBV oncoprotein, latent membrane protein 1 (LMP-1). LMP-1, which is expressed in NPC, has two
essential signaling domains within the carboxy terminus, termed C-terminal activation regions 1 (CTAR-1)
and CTAR-2. This study reveals that either signaling domain can activate the MMP-9 promoter and induce
MMP-9 activity; however, LMP-1 deletion mutants lacking either CTAR-1 or CTAR-2 had a decreased ability
to induce MMP-9 expression. The deletion of both activation regions completely abolished the induction of
MMP-9 activity, while the cotransfection of both the CTAR-1 and CTAR-2 deletion mutants restored MMP-9
activity to levels produced by wild-type LMP-1. The NF-kB and activator protein 1 (AP-1) binding sites in the
MMP-9 promoter were essential for the activation of MMP-9 gene expression by both CTAR-1 and CTAR-2.
The induction of MMP-9 expression by LMP-1 and both CTAR-1 and CTAR-2 mutants was blocked by the
overexpression of IkB. The tumor necrosis factor receptor-associated factor (TRAF) pathway also contributed
to the activation of the MMP-9 promoter as shown by the use of TRAF-2 and TRAF-3 dominant-negative
constructs. These data indicate that the activation of both the NF-kB and AP-1 pathways by LMP-1, CTAR-1,
and CTAR-2 is necessary for the activation of MMP-9 expression. In NPC, LMP-1 may contribute to inva-
siveness and metastasis through the induction of MMP-9 transcription and enzymatic activity.
Epstein-Barr virus (EBV), a ubiquitous human gamma her-
pesvirus, is associated with several malignant tumors such as
endemic Burkitt’s lymphoma, Hodgkin’s disease, and nasopha-
ryngeal carcinoma (NPC) (23, 46, 49, 60). EBV establishes a
latent infection in human B lymphocytes, and infection in vitro
results in immortalization (25). Latent membrane protein 1
(LMP-1) is considered the principal oncoprotein of EBV and
is essential for lymphocyte immortalization (21). LMP-1 ex-
pression has also been detected in rare examples of preinvasive
NPC lesions, suggesting that LMP-1 expression is an important
contributor to the development of NPC (44). LMP-1 is an
integral membrane protein consisting of 386 amino acids (aa).
Six transmembrane spanning regions (162 aa) connect a short
N-terminal cytoplasmic domain (24 aa) with a long C-terminal
cytoplasmic domain (200 aa) (10). Mutational analysis has
identified two activation domains in the C terminus of LMP-1:
C-terminal activation region 1 (CTAR-1) (residues 187 to 231)
and CTAR-2 (residues 351 to 386) (14, 37). LMP-1 associates
with the tumor necrosis factor receptor family-associated fac-
tors (TRAFs) through a TRAF interaction domain within
CTAR-1 (8, 30, 34, 35). TRAF-2 is of particular interest as it
mediates the activation of the transcriptional factor NF-kB,
following interaction with LMP-1 (8, 22, 34, 48). TRAF-1 and
TRAF-3 strongly associate with CTAR-1 and modulate the
activation of NF-kB (6, 34, 36, 50). CTAR-2 is a stronger
activator of NF-kB than CTAR-1 in reporter assays (11, 14, 37)
and has recently been shown to interact with the tumor necro-
sis factor receptor adaptor protein TRADD (19). Several stud-
ies have indicated that LMP-1 activates the c-Jun N-terminal
kinase (JNK) pathway through CTAR-2 but not CTAR-1 (9,
12, 24).
NPC is a highly metastatic and invasive malignant tumor in
which the EBV genes encoding LMP-1, LMP-2A and -2B, and
EBNA-1 are expressed. Essential steps in the process of tumor
invasion and metastasis include the degradation of the extra-
cellular matrix (ECM) and basement membrane (BM). The
invasion of the BM by tumor cells is thought to be one of the
critical steps in metastasis, which includes sequential multistep
processes (26, 40). Many proteolytic enzymes degrade compo-
nents of the ECM and BM (39, 45). Among these, the matrix
metalloproteinases (MMPs) are attractive candidates for en-
zymes required for tumor metastasis. The MMPs contain a zinc
ion at their active sites and can degrade native collagens and
other ECM components (27, 31). The MMP family includes
four types of collagenase (MMP-1, -8, -13, and -18), three types
of stromelysin (MMP-3, -10, and -11), and the 72- and 92-kDa
type IV gelatinases or collagenases (MMP-2 and MMP-9) (18).
Several membrane-type MMPs that activate pro-MMP-2 to
activate MMP2 have also been identified recently (51, 58).
* Corresponding author. Mailing address: Lineberger Comprehen-
sive Cancer Center, University of North Carolina School of Medicine,
Chapel Hill, NC 27599. Phone: (919) 966-1701. Fax: (919) 966-3015.
E-mail: nrt@med.unc.edu.
5548
MMP activity is tightly regulated by the following steps: (i)
control of gene transcription, (ii) activation of the latent form
of the enzyme to its active form by eliminating an N-terminal
peptide, and (iii) regulation by endogenous proteins known as
tissue inhibitors of metalloproteinases (7, 32). As type IV col-
lagen is one of the integral components of BM, the uncon-
trolled expression of two type IV collagenases, MMP-2 and
MMP-9, is believed to play a critical role in the invasion of BM
by tumor cells (28). MMP-2 and MMP-9 are often expressed by
tumor cells, but their expression is not always coordinated with
that of MMP-1 and MMP-3 (52). The release of MMP-2
and/or MMP-9 has been associated with metastasis in a variety
of model systems (2, 13, 55–57). The expression of MMP-2 and
that of MMP-9 are not necessarily linked, which suggests an
independent expression pattern for both proteinases (42). The
promoters for MMP-2 and MMP-9 differ markedly, with the
MMP-9 promoter having several putative activator protein 1
(AP-1) and NF-kB binding sites not found in the MMP-2
promoter (15, 16, 53). Pro-MMP-2 is activated to MMP-2 by
membrane-type MMPs (51, 58); however, activators of MMP-9
expression or activity have not been reported.
We have recently shown that the expression of MMP-9, but
not that of MMP-2, was induced by the EBV oncoprotein
LMP-1 (59). This study reveals that both LMP-1 activation
domains, CTAR-1 and CTAR-2, contribute to the full activa-
tion of the MMP-9 promoter and the induction of MMP-9
enzymatic activity through the activation of the NF-kB and
AP-1 transcription factors.
MATERIALS AND METHODS
Cell lines. C33A epithelial cells, derived from a human cervical carcinoma,
were grown at 37°C in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (Sigma) and antibiotics.
Plasmids. The LMP-1 open reading frame was subcloned downstream of the
cytomegalovirus (CMV) immediate-early promoter into the EcoRI site of
pcDNA3. A series of 59 flanking sequences of MMP-9 were inserted upstream of
the chloramphenicol acetyltransferase (CAT) reporter gene as described previ-
ously (52). The CMV immediate-early promoter-driven IkB expression plasmid
was obtained from Albert Baldwin (54). Constructs TRAF-2 dominant negative
(DN), containing aa 98 to 501, and TRAF-3DN, containing aa 345 to 568, were
cloned into the pSG5 vector, which contains the simian virus 40 early promoter
and intron sequences from the rabbit b-globin gene (Stratagene). All the LMP-1
mutants were cloned into the EcoRI site of the pcDNA3 expression vector and
have been previously described (34, 36).
Transient transfection and conditioned media. The transfection of C33A cells
was carried out with 5 3 105 cells per 60-mm-diameter dish with the use of
Lipofectamine (GIBCO/BRL) following the manufacturer’s protocol. Five mi-
crograms of appropriate reporter and effector plasmids were transfected. Trans-
fected cells were cultured in DMEM with 10% fetal bovine serum overnight and
then in a serum-free medium (OPTI-MEM I; GIBCO/BRL) without antibiotics
for 5 h at 37°C. Transfection efficiency was monitored by cotransfection with a
b-galactosidase reporter construct.
Western blot analysis. C33A cells were harvested 48 h after transfection with
FLAG-LMP mutants. Whole cell extracts were prepared by washing cells once in
cold phosphate-buffered saline solution and then lysing them in 500 ml of lysis
buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 5 mM EDTA, 0.5% Nonidet
P-40, 5 mM dithiothreitol, 0.2 mM Na orthovanadate, 100 mM NaF, 1 mM
phenylmethylsulfonyl fluoride, 10 mg of aprotinin per ml, 5 mg of leupeptin per
ml) with repeated freezing and thawing. The supernatant fluid was clarified by
centrifugation and was stored at 280°C until use. After sodium dodecyl sulfate
(SDS)-polyacrylamide gel electrophoresis, the proteins were transferred to Ni-
troPlus membranes (Micron Separations Inc.) with the Hoefer semidry transfer
apparatus. Nonspecific reactivity was blocked by incubation overnight in Tris-
buffered saline solution containing 0.1% Tween 20 and 5% nonfat dried milk.
The membrane was then incubated with a primary antibody to FLAG protein
(Santa Cruz Biotechnology, Inc.; 1:200 dilution [34]). A secondary antibody
(1:2,000 dilution) was used to detect the bound primary antibody. The reactive
protein was detected by enhanced chemiluminescence (Amersham).
CAT reporter assay. CAT assays were performed with extracts of C33A cells
after transient transfection. The construction of the MMP-9 promoter reporter
series has been described previously (52). Cells were incubated 48 h after trans-
fection in DMEM with 10% fetal bovine serum and antibiotics and then har-
vested; acetylated [14C]chloramphenicol was quantitated with a PhosphorImager
(Molecular Dynamics). The data were evaluated by comparison with the trans-
fection efficiency of b-galactosidase.
Gelatin zymography. MMP-2 and MMP-9 were assayed for gelatinolytic ac-
tivity by means of gelatin zymography as reported previously (59). The condi-
tioned medium was mixed with an SDS sample buffer (50 mM Tris-HCl [pH 6.8],
FIG. 1. (A) Schematic representation of wild-type (WT) and mutant LMP-1 proteins. LMP-1 consists of a 23-aa N-terminal cytoplasmic domain, six hydrophobic
transmembrane domains, and a 200-aa C-terminal cytoplasmic domain, in which two regions important for NF-kB activation and phenotypic changes have been
identified, CTAR-1 (residues 187 to 231) and CTAR-2 (residues 352 to 386). TRAFs interact with CTAR-1 but not with CTAR-2. LMP 1-187 and LMP 1-231 mutants
contain stop codons following amino acids 187 and 231, respectively. The LMP 1-187 mutant has the entire carboxy-terminal domain deleted, while LMP 1-231 has only
CTAR-1 and LMP del 187-351 has only CTAR-2. Each plasmid contains a FLAG expression sequence in the amino acid terminus. (B) Immunoblot analysis of
FLAG–LMP-1 wild-type (WT) and mutant proteins. The FLAG–LMP-1 mutant proteins are identified after transfection into C33A cells.
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10% glycerol, 1% SDS, 0.01% bromophenol blue) in the absence of a reducing
agent to denature MMPs and to dissociate any complexes with tissue inhibitors
of metalloproteinases. The mixture was then incubated at 37°C for 20 min, and
SDS-polyacrylamide gel electrophoresis (containing gelatin at a final concentra-
tion of 0.1%) was performed. After electrophoresis, the gel was rinsed in 2.5%
Triton X-100 for 1 h and then incubated for 24 h at 37°C in a solution containing
50 mM Tris-HCl (pH 7.6), 150 mM NaCl, 10 mM CaCl2, and 0.02% NaN3. The
MMPs were identified following staining of the gel in 0.1% Coomassie blue R250
(Sigma) dissolved in 40% methanol–10% acetic acid and destaining in the same
solution without Coomassie blue. Gelatinolytic activity was visualized as a clear
band against a dark background of stained gelatin. This is the most sensitive
method for the identification of MMP-2 and MMP-9. MMP-2 is detected by the
clear band appearing at 72 kDa, and MMP-9 is detected by the one at 92 kDa
(18, 32, 51, 58).
Electrophoretic mobility shift assay (EMSA). Nuclear extracts were prepared
from C33A cells transfected with LMP-1 and its mutant-expressing plasmids
(43). Synthetic oligonucleotides used for probes were identical to the NF-kB or
AP-1 nuclear factor binding sequences in the promoter region of MMP-9 (52).
The oligonucleotides were labeled with [a-32P]CTP with the use of Klenow DNA
polymerase. The unlabeled oligonucleotides were used for competition. Nuclear
extracts were incubated in a buffer containing 12 mM HEPES, 12% glycerol, 4
mM Tris-HCl (pH 7.9), 1 mM EDTA, and 3 mg of poly(dI-dC) with the probe
labeled at a rate of 50,000 cpm. The mixture was analyzed on a 4.8% polyacryl-
amide gel in 0.53 TBE buffer (90 mM Tris–64.6 mM boric acid–2.5 mM EDTA,
pH 8.3).
RESULTS
LMP-1 deletion mutants and polypeptides. The panel of
mutants used in this study is shown schematically in Fig. 1A
(14, 37). These constructs were cloned into the pcDNA3 vector
(Invitrogen), and a FLAG epitope was inserted at the amino
terminus to facilitate the detection of protein expression. The
expression of proteins of expected size from LMP-1 and the
mutated constructs was verified by transfecting each plasmid
into EBV-negative C33A cells and assaying by Western blot-
ting with the FLAG antibody. As illustrated in Fig. 1B, all
mutant LMP-1 polypeptides were expressed.
MMP-9 activity in cells transfected with LMP-1 deletion
mutants. Analysis of MMP gelatinolytic activity revealed an
increase in MMP-9 activity in C33A cells transfected with
wild-type LMP-1 (Fig. 2A). The ratio of MMP-9/MMP-2 ac-
tivity, as measured by reverse imaging and densitometric anal-
ysis (5), indicated that LMP-1 enhanced activity approximately
sixfold above that of the control (Fig. 2B). The LMP-1 mutant
lacking the entire carboxy terminus (LMP 1-187) was com-
pletely unable to induce MMP-9 activity. The mutants that
retained either CTAR-1 (LMP 1-231) or CTAR-2 (LMP del
187-351) had reduced levels of MMP-9 gelatinolytic activity
with 66 and 84% of the activity of LMP1, respectively. Inter-
estingly, the coexpression of the deletion mutants LMP 1-231
and LMP del 187-351 restored full activity, suggesting that
both domains contribute additively to MMP-9 activation. The
levels of the 72-kDa MMP-2 activity were unchanged by LMP-1
or any of the mutants (Fig. 2A).
Analyses of the MMP-9 promoter revealed that LMP-1 ac-
tivated the transcription of MMP-9 expression construct with a
2.6-fold increase over the vector control. LMP 1-187 did not
transactivate the MMP-9 promoter. The deletion mutants
LMP 1-231 and LMP del 187-351 had reduced transactivation,
with LMP 1-231 and LMP del 187-351 retaining 50 and 72% of
LMP1 transactivation, respectively (Fig. 2C). These data indi-
cated a close correlation between the direct measurement of
MMP-9 enzyme activity and the transactivation of the MMP-9
promoter. These experiments also show that either activation
region of LMP-1, CTAR-1 or CTAR-2, can activate the MMP-9
promoter and induce MMP-9 activity; however, both domains are
required for maximal activity.
Identification of LMP-1-induced transcription factors that
activate the MMP-9 promoter. MMP activity is regulated by
the control of gene transcription and also by posttranslational
control. The MMP-9 promoter is primarily regulated by NF-
kB, AP-1, and, to a lesser extent, secretory protein 1 (7, 32, 59).
To determine the contribution of the CTAR-1 and CTAR-2
domains to the activation of NF-kB and AP-1 in the MMP-9
promoter, MMP-9 promoter constructs containing point mu-
FIG. 2. MMP-9 and MMP-2 activity in C33A cells transfected with LMP-1
and deletion mutants. (A) Gelatin zymography. Samples of C33A cells were
prepared as described in Materials and Methods. WT, wild type. (B) Ratio of
MMP-9/MMP-2 activity as measured by reverse imaging the data from gelatin
zymography and densitometric analysis. Solid bars represent the ratio of each
LMP-1 and deletion mutant. The mean values and standard deviations (error
bars) are the results of five experiments. (C) CAT assays. The effector plasmids
were cotransfected with full-length MMP-9 promoter CAT. The data were com-
pared with results from assays of transfection efficiency of b-galactosidase, and
activities were given relative to the activity of pcDNA3, which was defined as 1.
The mean values and standard deviations (error bars) represented were obtained
from five experiments.
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tations in the NF-kB or AP-1 sites were cotransfected with
LMP-1 or the LMP-1 mutants. The mutation of the NF-kB site
slightly increased the basal activity of the promoter by approx-
imately 5% (Fig. 3A), while the mutation of the AP-1 site
reduced basal activity by 16% (Fig. 3B). The mutation of the
NF-kB site (Fig. 3A) or the AP-1 site (Fig. 3B) abolished
transactivation by LMP-1 and both of the LMP-1 mutants.
These data indicate that both the NF-kB and AP-1 binding
sites are necessary for the activation of the MMP-9 promoter
and that both LMP-1 activation regions mediate transactiva-
tion through NF-kB and AP-1.
As reported previously, LMP-1 induces nuclear factors that
bind to NF-kB and AP-1 sequences in the MMP-9 promoter
region (59). Through the interaction of the TRAFs with
CTAR-1 and that of TRADD with CTAR-2, LMP-1 activates
NF-kB inducing kinase and JNK (1, 9, 24). Previous studies
have indicated that CTAR-2 is the more potent activator of
NF-kB (11, 14, 37) and that only CTAR-2 can activate JNK (9,
24). However, NF-kB activation by both domains is partially
inhibited by a dominant-negative deletion mutant of TRAF-2,
TRAF-2DN, suggesting that TRAF-2 is a common mediator
for NF-kB activation (22).
As the mutational analysis of the MMP-9 promoter indi-
cated that both domains activated transcription through both
the NF-kB and AP-1 sites, it was important to identify the
nuclear factors that bind to these sites. With the NF-kB se-
quence in the MMP-9 promoter used as the probe in an
EMSA, NF-kB activity was detected in C33A cells transfected
with LMP-1, LMP 1-231 (CTAR-1 only), LMP del 187-351
(CTAR-2 only), and LMP 1-231 combined with LMP del 187-
351 but not with LMP 1-187 (Fig. 4A). Two predominant
shifted bands were detected with all constructs. These data
confirmed that NF-kB is efficiently activated by both CTAR-1
and CTAR-2 (36).
In agreement with the promoter mutational analyses, an
increase in binding to the AP-1 sequence was also detected
with the same set of constructs (Fig. 4B). Previous studies have
indicated that only CTAR-2 activates JNK, and these data also
show that a greater amount of AP-1, detected by EMSA, is
induced by CTAR-2 (9, 24). However, both LMP-1 activation
regions activated AP-1 binding to the MMP-9 promoter and
required this site for transactivation (Fig. 3).
Regulation of the MMP-9 promoter through TRAF signal-
ing. In order to determine the involvement of TRAFs in me-
diating MMP-9 activation induced by the LMP-1 mutants,
C33A cells were transiently cotransfected with LMP-1 mutants
and plasmids expressing dominant-negative forms of TRAF-2
(TRAF-2DN) or TRAF-3 (TRAF-3DN). The expression of
TRAF-2DN has previously been shown to partially inhibit sig-
naling from both CTAR-1 and CTAR-2 (22). In this study,
TRAF-2DN reduced the activation by LMP-1 by 58%.
TRAF2-DN reduced LMP 1-231 by approximately 43% and
LMP del 187-351 by 20%. TRAF-2DN also reduced MMP-9
promoter transactivation by the combined mutants (LMP
1-231 plus LMP del 187-351) by 50% (Fig. 5A).
Previous studies have shown that the activation of NF-kB by
CTAR-1 but not CTAR-2 is inhibited by the expression of
TRAF-3DN (6, 22, 34). In this study, TRAF-3DN reduced the
transactivation of the MMP-9 promoter induced by LMP-1,
LMP 1-231, and the reconstruction plasmids by approximately
60% but did not affect transactivation by LMP del 187-351
(Fig. 5B). These data indicate that signaling from CTAR-1 is
mediated through both TRAF-2 and TRAF-3, that TRAF2
contributes to signaling from CTAR-2, and that both TRAF-2
FIG. 3. Mutational analysis of the cis elements required for LMP-1 and deletion mutants induced MMP-9 promoter activity. (A) Solid and open bars represent CAT
activity of the wild-type (WT) MMP-9 promoter and the mutated NF-kB binding site in the MMP-9 promoter in C33A cells. The data were compared with the
transfection efficiency of b-galactosidase, and activities were given relative to the activity of pcDNA3 with wild-type MMP-9 promoter, which was defined as 1. The mean
values and standard deviations (error bars) are the results of five experiments. (B) Solid and open bars represent CAT activities of wild-type (WT) MMP-9 promoter
and the mutated AP-1 binding site in the MMP-9 promoter, respectively, in C33A cells. The data were evaluated by the same method as that described for panel A.
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and TRAF-3 contribute to the activation of the MMP-9 pro-
moter.
IkB inhibits MMP-9 expression. The activation of NF-kB
and NF-kB binding is necessary for the activation of the
MMP-9 promoter (6, 22, 30, 34, 48). Therefore, the inhibitory
effect of a constitutively activated form of the NF-kB repressor,
IkB (17), on the induction of MMP-9 expression by the LMP
mutants was determined. In assays performed with the CAT
reporter construct, the expression of IkB abolished the induc-
tion of the MMP-9 promoter by LMP-1 and the LMP-1 mu-
tants (Fig. 6A). Analysis of MMP-9 activity detected by gelatin
zymography also indicated that the cotransfection of the IkB
plasmid with the LMP mutants repressed MMP-9 gelatinolytic
activity but did not affect the activity of MMP-2 (Fig. 6B and
C). The activation of MMP-9 assessed by gelatin zymography
correlated with the activation of the MMP-9 promoter. These
FIG. 4. Induction of NF-kB (A) and AP-1 (B) DNA-binding activity in cells transfected with wild-type (WT) LMP-1 and deletion mutants. Nuclear extracts from
C33A cells transfected with LMP-1 mutants were mixed with either NF-kB or AP-1 32P-labeled probes. Excesses of nonlabeled NF-kB and AP-1 probes (3100) were
used as competitors (NFkB, 59-GATCGGGTTGCCCCAGTGGAATTCCCCAGCCTT-39; AP-1, 59-GATCTTCTAGACCGGATGAGTCATAGCTG-39). Under-
lined letters indicate binding sequences in the promoter of the MMP-9 gene. NS, nonspecific binding.
FIG. 5. The effect of transient expression of TRAF-2DN or TRAF-3DN on MMP-9 transcriptional activity induced by wild-type (WT) LMP-1 or deletion mutants.
Solid bars represent the CAT activity of LMP-1 and deletion mutants, while open bars represent the CAT activity when cells were cotransfected with TRAF2-DN (A)
and TRAF-3DN (B). The data were compared with the transfection efficiency as determined by b-galactosidase assay, and activities were given relative to the activity
of pcDNA3 without TRAF-DN, which was defined as 1. The mean values and standard deviations (error bars) are the results of five experiments.
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data confirm that the activation of NF-kB is necessary to ac-
tivate the MMP-9 promoter.
DISCUSSION
LMP-1 is essential for the transformation of B lymphocytes
and has profound effects on cellular gene expression (4, 38). In
addition LMP-1 can activate the type IV collagenase MMP-9,
which is implicated in tumor invasion of BM (59). Whether this
effect is unique among the oncogenic viruses is unknown. The
two activation domains of LMP-1, CTAR-1 and CTAR-2, both
activate NF-kB yet also have distinct properties (14, 34, 37).
CTAR-1, which interacts with TRAFs, induces the expression
of the epidermal growth factor receptor through a pathway
distinct from NF-kB activation, as epidermal growth factor
receptor expression is not induced by CTAR-2 (34). In con-
trast, CTAR-2 has a greater ability to activate NF-kB in re-
porter gene assays (14, 34, 37) and is thought to be responsible
for JNK activation by LMP-1 (9, 24). As LMP-1 also induces
the expression of MMP-9, which is known to be regulated by
NF-kB and AP-1 (59), it was of interest to determine the
contribution of CTAR-1 and CTAR-2 to this transactivation.
The data presented here reveal that both CTAR-1 and
CTAR-2 of LMP-1 can activate the MMP-9 promoter and
induce MMP-9 activity and that the domains have an additive
effect for transactivation. These results suggest that the com-
plete activation of the MMP-9 promoter by LMP-1 requires
both CTAR-1 and CTAR-2, which can be present on separate
molecules. It is likely that the oligomerization of LMP-1, me-
diated by the transmembrane domain, results in complexes
that contain both signaling domains, albeit on separate mole-
cules.
Although previous studies have suggested that JNK activa-
tion is mediated through CTAR-2 (9, 24), in this study both
CTAR-1 and CTAR-2 induced AP-1, as detected by EMSA,
with CTAR-2 inducing a greater amount. CTAR-1 interacts
with TRAF-2 (8, 30, 34, 35), CTAR-2 interacts with TRADD,
which binds TRAF-2 (19), and both domains are partially
inhibited by TRAF-2DN. These results suggest that TRAF-2
signaling is a common pathway arising from these two do-
mains. TRAF-2 has previously been shown to activate both
NF-kB and JNK through distinct pathways (1, 20, 29, 41, 47).
Thus, it is not surprising that both CTAR-1 and CTAR-2
would activate both NF-kB and AP-1, as revealed by these
studies of the MMP-9 promoter. The previous studies of JNK
activation have analyzed JNK activity on a glutathione S-trans-
ferase–Jun substrate in the presence of overexpressed JNK-1
(9, 24, 29, 38). The data presented here detect activated AP-1
on an authentic AP-1 site in the MMP-9 promoter. This activ-
ity may reflect the activation of distinct JNK kinases in vivo or
indicate that CTAR-1 activates AP-1 through some other in-
direct mechanism.
The data also indicate that both NF-kB and AP-1 are essen-
tial for the activation of the MMP-9 promoter. The effects are
not additive; thus, the mutation of either the NF-kB or AP-1
site eliminates the transactivation of the promoter by LMP-1.
The complete inhibition of promoter activity by the constitu-
tive active form of IkB also indicates that NF-kB binding is
essential for MMP-9 promoter activity. These data suggest that
both the NF-kB and AP-1 sites must be occupied to initiate
transcription.
FIG. 6. IkB inhibits the enhancement of MMP-9 expression by LMP-1 or
deletion mutants. (A) CAT assays. The effector plasmids were cotransfected with
wild-type MMP-9 promoter CAT. Solid bars represent CAT activity of wild-type
(WT) LMP-1 or deletion mutants in the absence of the IkB effector plasmid.
Open bars represent CAT activity in the presence of the IkB effector plasmid.
The data were compared with the transfection efficiency of b-galactosidase, and
activities were given relative to the activity of pcDNA3 without the IkB effector
plasmid, which was defined as 1. The mean values and standard deviations (error
bars) are the results of five experiments. (B) Gelatin zymography. MMP-9 and
MMP-2 activity in C33A cells transfected with wild-type (WT) LMP-1 or mutants
in the presence (1) or absence (2) of the IkB effector plasmid. (C) Ratio of
MMP9/MMP2 activity as shown in Fig. 2B. Solid bars represent the ratio of
wild-type (WT) LMP-1 or deletion mutants in the absence of IkB, while open
bars show the ratio in the presence of IkB. The data shown are the mean values
and standard deviations (error bars) of five independent experiments.
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As NPC is a highly metastatic tumor with frequent expres-
sion of LMP-1 (3), the activation of MMP-9 may be an impor-
tant contributing factor to pathogenesis. The data presented
here reveal that NF-kB and AP-1 are both essential for this
activation. Thus, agents that specifically inhibit NF-kB activa-
tion or JNK activation may be effective in preventing the me-
tastasis of NPC (33). These findings suggest that the biologic
phenotype of tumors associated with EBV latency types in
which LMP-1 is expressed may include a potential for metas-
tasis.
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